



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

Report for the Application PartII with MSC: Czechia

Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab  
with Pembrolizumab) in Combination with Concurrent  
Chemoradiotherapy followed by MK7684A Versus Concurrent  
Chemoradiotherapy followed by Durvalumab in Participants with  
Unresectable, Locally Advanced, Stage III NSCLC (KEYVIBE-006)

2022-502752-31-00

## MSC: Czechia

Site: Fakultni Nemocnice Kralovske Vinohrady

**Department name:**

Oncology department

**Site Street Address:**

Srobarova 1150/50

**Site City:**

Prague

**Site Post Code:**

100 00

**Site Country:**

Czechia

**First Name:**

Renata

**Last Name:**

Soumarová

**Title:**

2

**Telephone number:**

+420724318145

**Email:**

renata.soumarova@fnkv.cz

Site: Fakultni Nemocnice Ostrava

**Department name:**

Oncology department

**Site Street Address:**

17. Listopadu 1790/5

**Site City:**

Ostrava

**Site Post Code:**

708 00

**Site Country:**

Czechia

**First Name:**

Jakub

**Last Name:**

Cvek

**Title:**

1

**Telephone number:**

+420597372124

**Email:**

jakub.cvek@fno.cz

Site: Masarykuv Onkologicky Ustav

**Department name:**

Oncology department

**Site Street Address:**

Zluty Kopec 543/7

**Site City:**

Brno-Stred

**Site Post Code:**

656 53

**Site Country:**

Czechia

**First Name:**

Stanislav

**Last Name:**

Špelda

**Title:**

1

**Telephone number:**

+420543136111

**Email:**

spelda@mou.cz